Zolbetuximab

CHEMBL2109427 Phase 4 已批准 Antibody
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Zolbetuximab is a chimeric monoclonal antibody targeting Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed on gastric and gastroesophageal junction tumor cells, that mediates antitumor activity through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) upon CLDN18.2 binding. It is approved in combination with chemotherapy for first-line treatment of HER2-negative, CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Its targetable tumor-selective expression makes CLDN18.2 a novel antigen in upper gastrointestinal malignancies.

治疗领域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Zolbetuximab is a chimeric monoclonal antibody targeting Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed on gastric and gastroesophageal junction tumor cells, that mediates antitumor activity through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) upon CLDN18.2 binding. It is approved in combination with chemotherapy for first-line treatment of HER2-negative, CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Its targetable tumor-selective expression makes CLDN18.2 a novel antigen in upper gastrointestinal malignancies.

Yes, Zolbetuximab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109427. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.